The Continuing Influence of PTAB Proceedings on Bio/Pharma Litigation (Live MBHB Webinar)

Tues., September 19, 2017 | 10:00-11:15 a.m. CT | Live MBHB Webinar via WebEx

Since becoming available nearly 5 years ago, inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) have become an increasingly popular mechanism to challenge bio/pharma patents. Both petitioners and patent owners can learn lessons from the hundreds of IPR petitions that have been filed challenging bio/pharma patents.

Join us as we discuss the following topics:

  • A look at who is using PTAB proceedings to challenge bio/pharma patents;
  • An analysis of how PTAB proceedings are impacting ANDA and biosimilar litigations;
  • A review of how bio/pharma patents have fared before the PTAB;
  • A discussion of strategies for petitioners and patent owners in IPRs challenging bio/pharma patents; and
  • A discussion of how the Supreme Court’s decision to grant cert in Oil States Energy Services will impact PTAB invalidity proceedings in the bio/pharma space



 MBHB partners Alison Baldwin and Paula Fritsch, Ph.D.


Access an archived audio version of this webinar here

NOTE: MCLE credit is not available for this archived recording.

McDonnell Boehnen Hulbert & Berghoff LLP is committed to educating clients and friends of the firm with respect to significant developments and trends in the areas of intellectual property law.